文章摘要

IL-22基因启动子区甲基化检测在宫颈癌中的临床意义

作者: 1肖 义森, 1潘 国基, 1杨 丽梅, 2李 雪梅
1 惠州仲恺高新区人民医院检验科,广东 惠州 516229
2 惠州仲恺高新区人民医院妇产科,广东 惠州 516229
通讯: 肖 义森 Email: 15018666751@163.com
DOI: 10.3978/j.issn.2095-6959.2017.12.015

摘要

目的:检测IL-22基因启动子区域甲基化修饰的改变,以明确IL-22激活的可能机制及其在宫颈癌中的临床意义。方法:选取2016年1月至2017年6月惠州仲恺高新区人民医院收治的宫颈癌患者104例,选取同期我院因子宫良性病变行子宫全切手术的患者60例作为对照。IL-22基因启动子甲基化使用特异性PCR(MSP)检测,ELISA检测IL-22因子表达。结果:宫颈癌患者IL-22启动子甲基化阳性率为32.7%(34/104)显著高于对照组的15.0%(9/60)(P<0.05),宫颈癌患者IL-22表达水平为(28.36±5.48) ng/L,显著高于对照组的(14.52±1.37) ng/L(P<0.01)。IL-22启动子甲基化阳性率和IL-22因子表达量在临床III,IV期患者为40.4%(19/47)和(30.71±6.11) ng/L,均显著高于I,II期的26.3%(15/57)和(27.42±4.74) ng/L(P<0.05);在淋巴结有转移患者为42.1%(16/38)和(31.02±6.58) ng/L,显著高于无转移的27.3%(18/66)和(27.42±4.74) ng/L(P<0.05);在中、低分化患者为36.6%(26/71)和(30.13±6.37) ng/L,显著高于高分化的24.2%(8/33)和(24.56±4.85) ng/L(P<0.05)。结论:宫颈癌患者中IL-22基因启动子高甲基化,IL-22表达增加可能参与宫颈癌的发生、发展和转移过程。
关键词: 宫颈癌;IL-22;甲基化修饰

Clinical significance of promoter region methylation of IL-22 gene in uterine cervical cancer

Authors: 1,2XIAO Yisen, 1,2PAN Guoji, 1,2YANG Limei, 3LI Xuemei
1 Department of Laboratory, Huizhou Zhongkai High-tech Zone of People’s Hospital,
2 Huizhou Guangdong 516229, China
3 Department of Obstetrics and Gynecology, Huizhou Zhongkai High-tech Zone of People’s Hospital, Huizhou Guangdong 516229, China

CorrespondingAuthor:XIAO Yisen
Email: 15018666751@163.com

Abstract

Objective: To detect promoter region methylation of IL-22 gene in uterine cervical cancer (UCC) and explore its clinical significance. Methods: One hundred and four uterine cervical cancer patients from Huizhou Zhongkai High-tech Zone of People’s Hospital were enrolled in this study. Another 60 patients who underwent total hysterectomy for benign diseases was used as control, during the same period. Methylation of the IL-22 promoter was detected using specific PCR (MSP). IL-22 expression was detected by ELISA. Results: The positive rate of IL-22 promoter methylation and IL-22 expression in UCC patients was 32.7% (34/104) and (28.36±5.48) ng/L, which was significantly higher than that of 15.0%(9/60) and (14.52±1.37) ng/L in control group (P<0.05). The positive rate of IL-22 methylation and IL-22 expression in III and IV stage group was 40.4% (19/47) and (30.71±6.11) ng/L, which was both higher than that of 26.3% (15/57) and (27.42±4.74) ng/L in I and II stage group (P<0.05). The positive rate of IL-22 methylation and IL-22 expression in lymph node metastasis group was 42.1% (16/38) and (31.02±6.58) ng/L, which was both higher than that of 27.3% (18/66) and (27.42±4.74) ng/L in non-lymph node metastasis group (P<0.05). The positive rate of IL-22 methylation and IL-22 expression in median and low differentiation group was 36.6% (26/71) and (30.13±6.37) ng/L, which was both higher than that of 24.2% (8/33) and (24.56±4.85) ng/L in well differentiation group (P<0.05). Conclusion: High-methylation of IL-22 was detected in UCC, which increased IL-22 expression. The expression changes may be involved in the occurrence, development and metastasis of cervical cancer.
Keywords: uterine cervical cancer; IL-22; methylation

Refbacks

  • There are currently no refbacks.